Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia
#910
Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.
Aim(s): To evaluate efficacy and tolerability of T mono- and combination therapy in advanced NETs.
Materials and methods: Twenty-seven patients (pts) with advanced NETs (10 pancreatic NETs, seven GI NETs, three bronchial carcinoids, two kidney NETs, one mediastinal and three NETs without primary) were treated with T in monotherapy (five pts) or combination regimens, which included T+nitrosourea derivatives (10 pts), T+irinotecan (seven pts), T+capecitabine (four pts) and combination with cisplatin (one pt). Primary tumor site was resected in 14 patients. Most of the patients received long-acting octreotide. Ten pts were chemotherapy-naive. The median time from initial diagnosis till treatment initiation was seven months. The mean age was 57 years (26-78), 12 females, 15 males. Tumor differentiation was as follows: Grade 1 in one patient (3.7%), Grade 2 in 24 patients (89%) and Grade 3 in two patients (7.3%).
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Gorbunova V, Markovich A, Orel N, Kuzminov A, Odintsova A,
Keywords: temozolomide, neuroendocrine tumors ,
To read the full abstract, please log into your ENETS Member account.